Duell J, Abrisqueta P, Andre M, Gaidano G, et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study. Haematologica 2023 Aug 31. doi: 10.3324/haematol.2023.283480.
PMID: 37646664